

## Site-Specific Codes for Neoadjuvant Therapy Treatment Effect

### **Schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, Ill-Defined Other**

*Neoadjuvant Therapy--Treatment Effect* data item [NAACCR #1634] is related to the *Neoadjuvant Therapy* data item [NAACCR #1632]. This data item records the findings from the post neoadjuvant therapy **surgical pathology report ONLY** when surgery is performed after neoadjuvant therapy. This set of codes applies to the schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, and Ill-Defined Other.

### **Coding Instructions**

1. ALWAYS code to **0**, no neoadjuvant therapy (not applicable), for the following schemas, except for death certificate only cases (DCO) (see Coding Instruction #3 below)
  - a. HemeRetic 00830
  - b. Ill-Defined Other 99999
  - c. Lymphoma (excluding CLL/SLL) 00790
  - d. Lymphoma CLL/SLL 00795
  - e. Mycosis Fungoides 00811
  - f. Plasma Cell Disorders 00822
  - g. Plasma Cell Myeloma 00821
  - h. Primary Cutaneous Lymphoma (excluding MF and SS) 00812
2. Assign the appropriate code using the set of Site-Specific Codes for Neoadjuvant Therapy--Treatment Effect (Appendix C) that corresponds to the primary site when an organ is the primary site for a lymphoma
3. Assign code 9 for DCOs